Evaluate CHRS stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in CHRS? | Glauxie AI

Q: What are the risks of investing in CHRS?

Coherus Oncology, Inc. (CHRS) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Dennis Lanfear. Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to... Employees: 147.

Q: How much debt does CHRS have?

Review CHRS total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is CHRS a good long-term investment?

Evaluate CHRS as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in CHRS?

🦉

Coherus Oncology, Inc. (CHRS)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEODennis Lanfear

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation...

Key Executives

Name	Title
Andy Rittenberg	Chief Legal Officer
Arvind Sood	Chief Strategy & Corporate Affairs Officer
Bryan J. McMichael	Chief Financial Officer
Carrie Graham	Vice President of Investor Relations & Advocacy
Dennis Lanfear	Chairman, President & Chief Executive Officer
Michael Chen	Senior Vice President of Commercial Analytics & Trade

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

CHRS Profile Financials

Is CHRS stock safe? How much debt does CHRS have? Is CHRS a good long-term investment?